1 active not recruiting, 1 completed, 1 not yet recruiting, 1 recruiting. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Completed 1, Not yet recruiting 1, Withdrawn 1 |
Follow Malignant Pleural Mesothelioma, Advanced: new trials by email Literature Review of Malignant Pleural Mesothelioma, Advanced trials Research Report on Malignant Pleural Mesothelioma, Advanced
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma Ivonescimab Combined With Chemotherapy - Malignant Pleural Mesothelioma, Advanced | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 78 | 2026-11-01 | 2026-10-21 |
| CT-95 in Advanced Cancers Associated With Mesothelin Expression CT-95 - Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer | Phase 1 | Recruiting | Context Therapeutics Inc. | 70 | 2025-03-31 | 2026-06-12 |
| Safety and Preliminary Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma Ivonescimab Combined With Chemotherapy - Malignant Pleural Mesothelioma, Advanced | Phase 1 | Active not recruiting | Ruijin Hospital | 9 | 2025-03-12 | 2026-10-21 |
| Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma Oncolytic Adenovirus H101, Programmed death receptor-1 inhibitor - Malignant Pleural Mesothelioma, Advanced | Unknown | Tianjin Medical University Second Hospital | 15 | 2023-07-20 | 2023-09-11 | |
| A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma Atezolizumab - Malignant Pleural Mesothelioma, Advanced, Malignant Pleural Mesothelioma, Unresectable | Phase 2 | Withdrawn | Health Pharma Professional Research | 2020-08-01 | 2021-05-13 | |
| Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. Lurbinectedin - Malignant Pleural Mesothelioma, Advanced | Phase 2 | Completed | Swiss Cancer Institute | 42 | 2017-09-28 | 2021-07-14 |
Mesothelioma, Malignant (6) · Carcinoma, Ovarian Epithelial (1) · Colorectal Neoplasms (1) · Mesothelioma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Thoracic Neoplasms (1)
Adenoma (6) · Lung Diseases (6) · Lung Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Glandular and Epithelial (6) · Neoplasms, Mesothelial (6) · Pleural Neoplasms (6) · Respiratory Tract Diseases (6) · Respiratory Tract Neoplasms (6) · Mesothelioma (5) · Neoplasms (5) · Thoracic Neoplasms (5) · Adnexal Diseases (1) · Carcinoma (1)
Drug Therapy (2) · PM 01183 (1) · atezolizumab (1)
Ruijin Hospital (2) · Context Therapeutics Inc. (1) · Health Pharma Professional Research (1) · Swiss Cancer Institute (1) · Tianjin Medical University Second Hospital (1)
China (3) · Italy (1) · Mexico (1) · Switzerland (1) · United States (1)
Federica Grosso, MD (1) · Jorge Arturo Alatorre Alexander, MD (1) · Karen Chagin, MD (1) · Miklos Pless, MD (1) · Roger von Moos, Prof (1) · Yannis Metaxas, MD (1)
2017 (1)